Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study
Nicla La Verde(ASST Fatebenefratelli Sacco), Sandro Barni, Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Claudia Bareggi(University of Milan), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Rossana Berardi(Marche Polytechnic University), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Raffaella Palumbo(Fondazione Salvatore Maugeri), Gabriella Farina(ASST Fatebenefratelli Sacco), Luca Porcu(Mario Negri Institute for Pharmacological Research), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Livio Blasi, Antonella Brunello(Istituto Oncologico Veneto), Anna Moretti(ASST Fatebenefratelli Sacco), Jennifer Foglietta(Ospedale Santa Maria), Elena Collovà(Aziende Socio Sanitarie Territoriale Ovest Milanese), Graziella Pinotti(Medica (Italy)), Marta Bonotto(University of Udine)
Cited by 17
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684